ES2377829T3 - Mutantes de Vif del HIV - Google Patents

Mutantes de Vif del HIV Download PDF

Info

Publication number
ES2377829T3
ES2377829T3 ES06765488T ES06765488T ES2377829T3 ES 2377829 T3 ES2377829 T3 ES 2377829T3 ES 06765488 T ES06765488 T ES 06765488T ES 06765488 T ES06765488 T ES 06765488T ES 2377829 T3 ES2377829 T3 ES 2377829T3
Authority
ES
Spain
Prior art keywords
vif
hiv
polynucleotide
cells
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06765488T
Other languages
English (en)
Spanish (es)
Inventor
Chiara Bovolenta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGC Biologics SpA
Original Assignee
MolMed SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0504770A external-priority patent/GB0504770D0/en
Priority claimed from GB0510888A external-priority patent/GB0510888D0/en
Application filed by MolMed SpA filed Critical MolMed SpA
Application granted granted Critical
Publication of ES2377829T3 publication Critical patent/ES2377829T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES06765488T 2005-03-08 2006-03-07 Mutantes de Vif del HIV Active ES2377829T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0504770 2005-03-08
GB0504770A GB0504770D0 (en) 2005-03-08 2005-03-08 HIV Vif
GB0510888 2005-05-26
GB0510888A GB0510888D0 (en) 2005-05-26 2005-05-26 Hiv vif
PCT/IB2006/001519 WO2006111866A2 (en) 2005-03-08 2006-03-07 Hiv vif mutants

Publications (1)

Publication Number Publication Date
ES2377829T3 true ES2377829T3 (es) 2012-04-02

Family

ID=37115522

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06765488T Active ES2377829T3 (es) 2005-03-08 2006-03-07 Mutantes de Vif del HIV

Country Status (9)

Country Link
US (1) US8912152B2 (enExample)
EP (1) EP1883649B1 (enExample)
JP (1) JP5324912B2 (enExample)
KR (1) KR101411272B1 (enExample)
AT (1) ATE533777T1 (enExample)
AU (1) AU2006238617B2 (enExample)
CA (1) CA2599525C (enExample)
ES (1) ES2377829T3 (enExample)
WO (1) WO2006111866A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015379A1 (en) 2009-08-05 2011-02-10 Nexigen Gbmh Human hcv-interacting proteins and methods of use
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
KR102458904B1 (ko) * 2020-06-19 2022-11-01 숙명여자대학교산학협력단 신규의 bmpr2 유전자 기능획득 돌연변이체 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
WO2005024422A2 (en) * 2003-05-23 2005-03-17 Oregon Health & Science University Methods for identifying inhibitors

Also Published As

Publication number Publication date
AU2006238617A1 (en) 2006-10-26
JP5324912B2 (ja) 2013-10-23
WO2006111866A2 (en) 2006-10-26
EP1883649A2 (en) 2008-02-06
CA2599525C (en) 2015-05-26
US8912152B2 (en) 2014-12-16
KR20070118624A (ko) 2007-12-17
CA2599525A1 (en) 2006-10-26
KR101411272B1 (ko) 2014-07-03
JP2008532510A (ja) 2008-08-21
ATE533777T1 (de) 2011-12-15
AU2006238617B2 (en) 2012-08-02
EP1883649B1 (en) 2011-11-16
US20080286248A1 (en) 2008-11-20
WO2006111866A3 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
ES2245042T3 (es) Vectores de lentivirus de no primates y sistemas de empaquetamiento.
US8287881B2 (en) Synthetic gagpol genes and their uses
US6323019B1 (en) Design of novel highly efficient HIV based packaging systems for gene therapy
US20110104789A1 (en) Non-integrating rev-dependent lentiviral vector and methods of using the same
Chen et al. Intra-and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody
ES2377829T3 (es) Mutantes de Vif del HIV
US20080226675A1 (en) Recombinant vector and use in gene therapy
AU2003242496B2 (en) Conjugate
Orita et al. p21X mRNA is expressed as a singly spliced pX transcript from defective provirus genomes having a partial delection of the pol-env region in human T-cell leukemia virus type 1-infected cells
Poluri et al. Genetic therapy for HIV/AIDS
US20110294219A1 (en) Use of the foamy virus bet protein for inactivating apobec
CN101137666B (zh) HIV Vif突变体
ES2370888T3 (es) Modulación de la producción de retrovirus por apobec4.
US20120034693A1 (en) Recombinant vector and use in gene therapy
ES2220994T3 (es) Composicion y procedimiento para impartir resistividad a las celulas frente a sobreinfecciones por vih.
Tung et al. Characterization of antisense RNA‐mediated inhibition of SIV replication
Raymond Control of acute HIV-1 infection: Intracellular immunization with Herpesvirus saimiri transforming proteins, Tip and StpC and the effect of opiate abuse
STEVENSON Novel HIV-1 Therapeutic Targets: Accessory Functions
Manicone Functional interactions of the Tax and p13 proteins of Human T-cell Leukemia Virus Type I
Serio Novel HIV-1 therapeutic agents based on virion-targeted viral proteins
Kirmaier Replication and Persistence of Primate Lentiviruses
Hiraragi Study of lentiviral vectors for in utero gene transfer and functional analysis of human T-lymphotropic virus type 1 p13 (II)
Choudhary Regulation of Human T-cell Leukemia Virus Type 1 Infection and Replication
Camaur Roles of virion associated proteins in HIV-1 infectivity: Vif, Nef and the matrix tyrosine kinase
Li Cloning and expression of vaccinia virus complement control protein using human immunodeficiency virus vectors for gene therapy